Rare
lephants
Screener
Toggle theme
Novartis AG
NVSEF
·
Healthcare, Drug Manufacturers - General, Switzerland
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Total Cash from Operations:
$19.14B
Line Item
Value
% of Total
Capital Expenditures
$1.55B
8.1%
Other Investing
$3.18B
16.6%
Stock Repurchases
$9.12B
47.6%
Other Financing
$5.29B
27.6%
Net Cash Flow
$0
0.0%
Download CSV
